--- title: "NP47827 Multiple Sclerosis Medicines" ocid: "ocds-r6ebe6-0000846657" canonical_url: "https://d3tenders.com/contract/?ocid=ocds-r6ebe6-0000846657" markdown_url: "https://d3tenders.com/contract/ocds-r6ebe6-0000846657.md" json_url: "https://d3tenders.com/contract/ocds-r6ebe6-0000846657.json" source: "Public Contracts Scotland" current_stage: "Planning" buyer: "The Common Services Agency (more commonly known as Public Services Delivery Scotland) (PSD Scotland)" published: "2026-10-26" --- # NP47827 Multiple Sclerosis Medicines Buyer: The Common Services Agency (more commonly known as Public Services Delivery Scotland) (PSD Scotland) Current stage: Planning OCID: ocds-r6ebe6-0000846657 [View canonical contract page](https://d3tenders.com/contract/?ocid=ocds-r6ebe6-0000846657) [Download OCDS JSON](https://d3tenders.com/contract/ocds-r6ebe6-0000846657.json) ## Summary Public Services Delivery Scotland (PSD Scotland) intends to establish a framework agreement for multiple sclerosis medicines for NHS Scotland. The medicines under consideration are glatiramer acetate, interferon beta-1a, teriflunomide, dimethyl fumarate, fingolimod, natalizumab and cladribine tablets; the proposed range may change. Supply would serve NHS bodies and Integrated Joint Boards across Scotland. This is a medicines supply procurement, classified under CPV 33600000. The three product groupings are glatiramer acetate, interferon beta-1a and natalizumab; fingolimod, teriflunomide and dimethyl fumarate; and cladribine tablets. This is at the planning stage: PSD Scotland has stated its intention to procure, but has not yet invited tenders. The buyer expects to publish a further notice on 22 January 2027. The estimated procurement value is £30,403,887, covering a maximum framework duration of 48 months, including the initial term and any extensions combined. The framework is planned in three lots. Each lot is intended to have multiple suppliers appointed by product line; the first lot is unranked, while the other two are ranked. The detailed goods and volumes are to be set out in the future tender documents. The data does not give a proposed procurement method or evaluation criteria. The procurement is likely to suit pharmaceutical manufacturers and medicine suppliers able to supply one or more of the seven multiple sclerosis treatments under consideration to NHS Scotland. Suppliers may want to assess capability across the three product groupings, since each is planned as a multi-supplier framework by product line rather than a single-supplier award. The product range is subject to change in response to litigation, so businesses should monitor developments affecting the medicines considered for inclusion. Suppliers with established supply arrangements for NHS Scotland and the capacity to serve NHS bodies and Integrated Joint Boards across the country are well placed to prepare. The proposed framework offers a route to supply through product-specific appointments, but the buyer has not yet set out detailed volumes or tender requirements. ## Notice The Authority seeks to establish a Framework Agreement covering Multiple Sclerosis medicines. The range of medicines under consideration for inclusion in the Framework Agreement are listed below (subject to removal or replacement due to a continually shifting litigation landscape): Glatiramer acetate Interferon beta-1a Teriflunomide Dimethyl fumarate Fingolimod Natalizumab Cladribine ### Lot Information Glatiramer acetate, Interferon beta-1a and Natalizumab Supply of Glatiramer acetate, Interferon beta-1a and Natalizumab to NHS Scotland. The Authority intends to award this Lot as an unranked multi supplier Framework Agreement per product line. Full details of Goods and volumes will be found within the ITT documents once published. Cladribine tablets Supply of cladribine tablets to NHS Scotland. The Authority intends to award this Lot as a ranked multi-supplier Framework Agreement per product line. Full details of Goods and volumes will be found within the ITT documents once published. Fingolimod, Teriflunomide and Dimethyl Fumarate Supply of Fingolimod, Teriflunomide and Dimethyl Fumarate to NHS Scotland. The Authority intends to award this Lot as a ranked multi-supplier Framework Agreement per product line. Full details of Goods and volumes will be found within the ITT documents once published. ## Key Details | Field | Value | | --- | --- | | Publication source | Public Contracts Scotland | | Latest notice | https://www.publiccontractsscotland.gov.uk/search/show/search_view.aspx?ID=OCT567400 | | Notice type | OJEU - F1 - Prior Information Notice | | Procurement type | Framework | | Procurement category | Goods | | Procurement method | Not Specified | | Procurement method details | Not specified | | Tender suitability | Not specified | | Awardee scale | Not specified | | All stages | Planning | ## Dates | Field | Value | | --- | --- | | Publication date | 26 Oct 2026 | | Submission deadline | Not specified | | Future notice date | 22 Jan 2027 | | Award date | Not specified | | Contract period | Not specified | | Recurrence | Not specified | ## Values | Field | Value | | --- | --- | | Tender value | £30,403,887 | | Lots value | Not specified | | Awards value | Not specified | | Contracts value | Not specified | ## Status | Field | Value | | --- | --- | | Tender status | Planned | | Lots status | Planned | | Awards status | Not specified | | Contracts status | Not specified | ## Buyer | Field | Value | | --- | --- | | Main buyer | The Common Services Agency (more commonly known as Public Services Delivery Scotland) (PSD Scotland) | | Locality | EDINBURGH | | Postcode area | Edinburgh | | Postcode | EH12 9EB | | Country | Scotland | | ITL 1 | TLM Scotland | | ITL 2 | TLM1 East Central Scotland | | ITL 3 | TLM13 City of Edinburgh | | Local authority | City of Edinburgh | | Electoral ward | Drum Brae/Gyle | | Westminster constituency | Edinburgh South West | | Delivery location | TLM Scotland | ## CPV Codes ### Divisions - 33 - Medical equipments, pharmaceuticals and personal care products ### Codes - 33600000 - Pharmaceutical products ## Release History - 26 Oct 2026 at 00:00 - Planning - OJEU - F1 - Prior Information Notice - https://www.publiccontractsscotland.gov.uk/search/show/search_view.aspx?ID=OCT567400 ## Documents - https://www.publiccontractsscotland.gov.uk/search/show/search_view.aspx?ID=OCT567400 NP47827 Multiple Sclerosis Medicines - The Authority seeks to establish a Framework Agreement covering Multiple Sclerosis medicines. The range of medicines under consideration for inclusion in the Framework Agreement are listed below (subject to removal or replacement due to a continually shifting litigation landscape): Glatiramer acetate Interferon beta-1a Teriflunomide Dimethyl fumarate Fingolimod Natalizumab Cladribine ## Notice URLs - http:// - http://publicservicesdelivery.scot/about/procurement/ - http://www.publiccontractsscotland.gov.uk/Search/Search_Switch.aspx?ID=846657 - https://api.publiccontractsscotland.gov.uk/v1/Notice?id=ocds-r6ebe6-0000846657 ## Provenance This Markdown file is an alternate public rendering of the D3 Tenders contract record. The canonical page is https://d3tenders.com/contract/?ocid=ocds-r6ebe6-0000846657. The underlying structured data is available as OCDS JSON at https://d3tenders.com/contract/ocds-r6ebe6-0000846657.json.